However, it has been recently demonstrated, in patient-derived tissue samples of NSCLC and colorectal cancer (CRC), that RAS mutational condition, a common mechanism of intrinsic resistance to EGFR inhibitors, is correlated to uPAR overexpression [131]. Here, PLAUR is linked to non-small cell lung carcinoma.